Home / Companies / Dianthus Therapeutics, Inc. / 22 May 2025
Dianthus Therapeutics, Inc.: meeting of 22 May 2025
Votes reported on Form N-PX, item by item
191 Form N-PX filers reported votes at the Dianthus Therapeutics, Inc. meeting of 22 May 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 72.4% of reported votes for; 26 filers withheld from or voted against at least one nominee.
236 vote records from 68 filers. 19 of the 68 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
263 vote records from 190 filers. 90 of the 185 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
118 vote records from 68 filers. 1 of the 68 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | Against * | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | Abstain or withhold * | Against * | For |
| State Street and SPDR | For | For | For |
| American Century | Abstain or withhold * | Against * | For |
| Invesco | For | Against * | For |
| Equitable | For | Against * | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | Against * | For |
| John Hancock and Manulife | Abstain or withhold * | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | Against * | For |
| J.P. Morgan | No report | For | No report |
| Goldman Sachs | For | Against * | For |
| PGIM and Prudential | No report | For | No report |
| Northern Trust and FlexShares | Split or no vote | For | For |
| SEI | For | For | For |
| T. Rowe Price | For | Against * | For |
| Lincoln Financial | For | For | For |
| Voya | For | Against * | For |
| Nationwide | For | For | For |
| Victory Capital | Abstain or withhold * | Against * | For |
| Brighthouse Funds | Abstain or withhold * | Against * | For |
| Guggenheim and Rydex | Abstain or withhold * | Against * | For |
| Columbia Threadneedle | For | Against * | For |
| BNY Mellon | No report | For | No report |
| Principal | Split or no vote | Against * | For |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| AllianceBernstein | Split or no vote | Against * | For |
| DWS | Abstain or withhold * | Against * | For |
| Janus Henderson | No report | Against * | No report |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Dianthus Therapeutics, Inc. meeting?
191 Form N-PX filers reported votes at the meeting of 22 May 2025. On say-on-pay, 90 of 185 voted against management (48.6%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Dianthus Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Dianthus Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Dianthus Therapeutics, Inc. with a meeting date within three days of 22 May 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.